Your browser doesn't support javascript.
loading
Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy.
Lacy, John M; Wilson, William A; Bole, Raevti; Chen, Li; Meigooni, Ali S; Rowland, Randall G; Clair, William H St.
Afiliação
  • Lacy JM; Department of Urology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
  • Wilson WA; Department of Radiation Oncology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
  • Bole R; University of Kentucky College of Medicine, Lexington, KY 40536, USA.
  • Chen L; Department of Biostatistics, University of Kentucky College of Public Health, Lexington, KY 40536, USA.
  • Meigooni AS; Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA.
  • Rowland RG; Department of Urology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
  • Clair WH; Department of Radiation Oncology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
Prostate Cancer ; 2016: 9561494, 2016.
Article em En | MEDLINE | ID: mdl-27092279
ABSTRACT
Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Computed tomography (CT) scans were evaluated; patients who had an underseeded portion of their prostate were considered for reimplantation. Results. The majority of the patients in this study (61.9%) were low risk and median presalvage PSA was 3.49 (range 17.41-1.68). Mean follow-up was 61 months. At last follow-up after reseeding, 11/21 (52.4%) were free of biochemical recurrence. There was a trend towards decreased freedom from biochemical recurrence in low risk patients (p = 0.12). International Prostate Symptom Scores (IPSS) increased at 3-month follow-up visits but decreased and were equivalent to baseline scores at 18 months. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, in our experience the side-effect profile after the second brachytherapy procedure was higher than after the first brachytherapy procedure. In this cohort of patients we demonstrate that approximately 50% oncologic control, low risk patients appear to have better outcomes than others.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article